Skip to main content

The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis

Abstract

Whether consolidation chemotherapy (CCT) after chemoradiotherapy (CRT) helps in the treatment of locally advanced non-small cell lung cancer (LA-NSCLC) is controversial. The aim of this meta-analysis was to evaluate the impact of CCT on overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicities in patients with inoperable LA-NSCLC. PubMed, Embase, The Cochrane Library, WanFang, VIP, and CNKI were searched to identify any relevant publications. After screening the literature and completing quality assessment and data extraction, the meta-analysis was performed using RevMan5.3 software. Ultimately, 5 eligible studies with a total of 1036 patients were selected for the present meta-analysis. The results of the analysis indicated that treatment of LA-NSCLC patients with CRT followed by CCT improved OS (pooled HR 0.85; 95% CI 0.73–0.99; P = 0.03), but did not improve PFS (pooled HR 0.78; 95% CI 0.60–1.02; P = 0.07) and ORR (P = 0.26). Although it could increase the risk of grade ≥3 infection (P = 0.04), it may not increase the risk of grade ≥3 radiation pneumonitis (P = 0.09) during the CCT period. CCT after concurrent CRT may provide additional benefits in the treatment of LA-NSCLC. Although this therapeutic strategy did not prolong PFS, further assessment is warranted.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

    Article  PubMed  Google Scholar 

  2. 2.

    Molina JR, Yang P, Cassivi SD et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584–594

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Aupérin A, Le Péchoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181–2190

    Article  PubMed  Google Scholar 

  5. 5.

    Curran WJ Jr, Paulus R, Langer CJ et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452–1460

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Ramnath N, Dilling TJ, Harris LJ et al (2013) Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(Suppl):e314S–e3140S

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Soon YY, Stockler MR, Askie LM et al (2009) Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 27:3277–3283

    Article  PubMed  Google Scholar 

  8. 8.

    Zhang X, Zang J, Xu J et al (2011) Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Chest 140:117–126

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Cortesi E, Moscetti L, Nelli F et al (2007) Induction therapy with paclitaxel and carboplatin followed by hyperfactionated radiotherapy plus weekly concurrent chemotherapy and subsequent consolidation therapy in unresectable locally advanced non-small-cell lung cancer. Tumori 93:133–137

    CAS  PubMed  Google Scholar 

  10. 10.

    Tsujino K, Kurata T, Yamamoto S et al (2013) Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. J Thorac Oncol 8:1181–1189

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Hanna N, Neubauer M, Yiannoutsos C et al (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and US Oncology. J Clin Oncol 26:5755–5760

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Davies AM, Chansky K, Lau DH et al (2006) Phase II study of consolidation paclitaxel after  concurrent  chemoradiation  in poor-risk  stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol 20;24(33):5242–5246

  13. 13.

    Yamamoto N, Goto K, Nishio M et al (2016) Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR, mutation-positive non-small-cell lung cancer. Int J Clin Oncol 1–9

  14. 14.

    Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Williamson PR, Smith CT, Hutton JL et al (2002) Aggregate data meta-analysis with time-to-event outcomes. Stat Med 21(22):3337–3351

    Article  PubMed  Google Scholar 

  16. 16.

    Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8(1):16

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Mutlu H, Arslan D, Gündüz Ş et al (2014) The optimal treatment modality in patients with T4N2M0 non-small cell lung cancer: the best choice may be definitive chemoradiotherapy followed by consolidation chemotherapy. Chemotherapy 60:107–111

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Ahn JS, Ahn YC, Kim JH et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-0414. J Clin Oncol 2015; 33:2660–2666

  19. 19.

    Liu L, Bi N, Ji Z et al (2015) Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy—retrospective analysis of 203 cases. BMC Cancer 15:715

    Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Jalal SI, Riggs HD, Melnyk A et al (2012) Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol 23:1730–1738

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Jett JR, Scott WJ, Rivera MP et al (2003) Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 123:221S–225S

    Article  PubMed  Google Scholar 

  22. 22.

    Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Fournel P, Robinet G, Thomas P et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienned’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23:5910–5917

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Decker RH, Lynch TJ (2012) Unmet challenges in the use of novel agents in locally advanced non-small-cell lung cancer. J Clin Oncol 30:582–584

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Bastos BR, Hatoum GF, Walker GR et al (2010) Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol 5:533–539

    Article  PubMed  Google Scholar 

  26. 26.

    Eroglu C, Orhan O, Unal D, et al. Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer. Ann Thorac Med 201;8(2): 109, 3

  27. 27.

    Gandara DR, Chansky K, Albain KS et al (2006) Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group study (S9504). Clin Lung Cancer 8(2):116–121

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Albain KS, Crowley JJ, Turrisi AT et al (2002) Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20(16):3454–3460

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Horinouchi H, Sekine I, Sumi M et al (2013) Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer. Cancer Sci 104:93–97

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Takigawa N, Kiura K, Segawa Y et al (2006) Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer. Br J Cancer 95:1142–1144

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The present study was funded by The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology. The authors would like to thank the American Journal Experts Service Center for their excellent language editing service.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Shegan Gao.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wang, X., Ding, X., Kong, D. et al. The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis. Int J Clin Oncol 22, 229–236 (2017). https://doi.org/10.1007/s10147-016-1074-x

Download citation

Keywords

  • Non-small cell lung cancer
  • Chemoradiotherapy
  • Consolidation chemotherapy
  • Meta-analysis